870P POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC).
Saved in:
| Title: | 870P POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). |
|---|---|
| Authors: | Forster, M.D.1 (AUTHOR), Mason, J.2 (AUTHOR), Moleron, R.3 (AUTHOR), Sacco, J.J.4 (AUTHOR), Beasley, M.5 (AUTHOR), Reis Ferreira, M.6 (AUTHOR), Srinivasan, D.7 (AUTHOR), Yip, K.8 (AUTHOR), Stewart, G.9 (AUTHOR), Chiu, K.10 (AUTHOR), Ward, A.11 (AUTHOR), Metcalf, R.12 (AUTHOR), Adedoyin, T.13 (AUTHOR), Begum, R.14 (AUTHOR), Chiwewe, M.13 (AUTHOR), Poole, K.13 (AUTHOR), Spanswick, V.15 (AUTHOR), Pathak, Y.15 (AUTHOR), Counsell, N.16 (AUTHOR), Rashid, M.K.17 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS623-S624. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
